<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: conjunction with", fill: "#e5aa70"},
{source: "9: conjunction with", target: "9: product lines", fill: "#e5aa70"},
{source: "9: product lines", target: "9: North American ", fill: "#e5aa70"},
{source: "9: North American ", target: "9: lead product", fill: "#e5aa70"},
{source: "9: lead product", target: "9: ESTRASORB ", fill: "#e5aa70"},
{source: "9: ESTRASORB ", target: "9: company from", fill: "#e5aa70"},
{source: "9: company from", target: "9: development", fill: "#e5aa70"},
{source: "9: development", target: "9: commercialization", fill: "#e5aa70"},
{source: "9: commercialization", target: "9: specialty pharmaceutical products", fill: "#e5aa70"},
{source: "9: specialty pharmaceutical products", target: "9: products using", fill: "#e5aa70"},
{source: "9: products using", target: "9: proprietary drug delivery", fill: "#e5aa70"},
{source: "9: proprietary drug delivery", target: "9: biological platforms", fill: "#e5aa70"},
{source: "9: conjunction with", target: "11: development activities on areas", fill: "#ffd300"},
{source: "11: development activities on areas", target: "11: on technologies", fill: "#ffd300"},
{source: "11: development activities on areas", target: "16: cases preclinical", fill: "#df00ff"},
{source: "16: cases preclinical", target: "16: clinical studies", fill: "#df00ff"},
{source: "16: clinical studies", target: "16: product candidate", fill: "#df00ff"},
{source: "16: product candidate", target: "16: efficacious", fill: "#df00ff"},
{source: "16: cases preclinical", target: "20: product candidates", fill: "#ffe135"},
{source: "20: product candidates", target: "20: development with", fill: "#ffe135"},
{source: "20: development with", target: "20: technologies", fill: "#ffe135"},
{source: "20: technologies", target: "20: establish successful government", fill: "#ffe135"},
{source: "20: establish successful government", target: "20: thirdparty", fill: "#ffe135"},
{source: "20: thirdparty", target: "20: relationships", fill: "#ffe135"},
{source: "20: product candidates", target: "34: partners fail", fill: "#da3287"},
{source: "34: partners fail", target: "34: existing agreements", fill: "#da3287"},
{source: "34: existing agreements", target: "34: establish agreements as", fill: "#da3287"},
{source: "34: establish agreements as", target: "34: necessary", fill: "#da3287"},
{source: "34: necessary", target: "34: research development", fill: "#da3287"},
{source: "34: research development", target: "34: manufacturing", fill: "#da3287"},
{source: "34: manufacturing", target: "34: commercialization activities solely at", fill: "#da3287"},
{source: "34: partners fail", target: "51: covering various", fill: "#fc0"},
{source: "51: covering various", target: "51: candidates", fill: "#fc0"},
{source: "51: candidates", target: "51: composition methods", fill: "#fc0"},
{source: "51: composition methods", target: "51: manufacture", fill: "#fc0"},
{source: "51: manufacture", target: "51: provide us with", fill: "#fc0"},
{source: "51: provide us with", target: "51: development", fill: "#fc0"},
{source: "51: development", target: "51: competing products", fill: "#fc0"},
{source: "51: covering various", target: "START_HERE", fill: "#fc0"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estradiol_(medication)">Estradiol (medication)</a></td>
      <td>Estradiol (E2) is a medication and naturally occurring steroid hormone. It is an estrogen and is used mainly in menopausal hormone therapy and to treat low sex hormone levels in women.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Polysorbate_80">Polysorbate 80</a></td>
      <td>Polysorbate 80 is a nonionic surfactant and emulsifier often used in pharmaceuticals, foods, and cosmetics. This synthetic compound is a viscous, water-soluble yellow liquid.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Graceway_Pharmaceuticals">Graceway Pharmaceuticals</a></td>
      <td>Graceway Pharmaceuticals was a USA LLC based in Tennessee.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estradiol_valerate">Estradiol valerate</a></td>
      <td>Estradiol valerate (EV), sold for use by mouth under the brand name Progynova and Primiwal E4 and for use by injection under the brand names Delestrogen and Progynon Depot among others, is an estrogen medication. In women, it is used in hormone therapy for menopausal symptoms and low estrogen levels, hormone therapy for transgender women, and in hormonal birth control.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacokinetics_of_estradiol">Pharmacokinetics of estradiol</a></td>
      <td>The pharmacology of estradiol, an estrogen medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.Estradiol is a naturally occurring and bioidentical estrogen, or an agonist of the estrogen receptor, the biological target of estrogens like endogenous estradiol. Due to its estrogenic activity, estradiol has antigonadotropic effects and can inhibit fertility and suppress sex hormone production in both women and men.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estradiol_cypionate">Estradiol cypionate</a></td>
      <td>Estradiol cypionate (EC), sold under the brand name Depo-Estradiol among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in cis women, in hormone therapy for trans women, and in hormonal birth control for cis women. It is given by injection into muscle once every 1 to 4 weeks.Side effects of estradiol cypionate include breast tenderness, breast enlargement, nausea, headache, and fluid retention.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estradiol_benzoate">Estradiol benzoate</a></td>
      <td>Estradiol benzoate (EB), sold under the brand name Progynon-B among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for transgender women, and in the treatment of gynecological disorders. It is also used in the treatment of prostate cancer in men.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_drugs:_Eq–Es">List of drugs: Eq–Es</a></td>
      <td>This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_estrogens_available_in_the_United_States">List of estrogens available in the United States</a></td>
      <td>This is a complete list of estrogens and formulations that are approved by the FDA and available in the United States. Estrogens are used as hormonal contraceptives, in hormone replacement therapy, and in the treatment of gynecological disorders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porcelain_manufacturing_companies_in_Europe">Porcelain manufacturing companies in Europe</a></td>
      <td>Porcelain manufacturing companies are firms which manufacture porcelain.\n\n\n== European porcelain manufacturers before the 18th century ==\nThe table below lists European manufacturers of porcelain established before the 18th century.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NOVAVAX INC      Item 1A Risk Factors          You <font color="blue">should carefully</font> consider the <font color="blue">following risk factors</font> in evaluating     our business</td>
    </tr>
    <tr>
      <td>Some of the <font color="blue">risks described</font> relate <font color="blue">principally</font> to our business     and the industry in which we operate</td>
    </tr>
    <tr>
      <td>Others relate <font color="blue">principally</font> to the     securities  market  and  ownership  of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The risks and     <font color="blue"><font color="blue">uncertainties</font> described</font> below are not the <font color="blue">only ones facing us</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Additional </font>    </font>risks and <font color="blue">uncertainties</font> that we are unaware of, or that we currently deem     immaterial, also may become important factors that <font color="blue">affect us</font></td>
    </tr>
    <tr>
      <td>If any of the     <font color="blue">following risks</font> occur, our business, <font color="blue">financial condition</font> or results of     <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should also</font>     consider the other information included in this Annual report on Form 10-K     for the 2005 fiscal year</td>
    </tr>
    <tr>
      <td>We have <font color="blue">repositioned ourselves from</font> a <font color="blue">specialty bio<font color="blue">pharmaceutical</font></font>     company to a <font color="blue">bio<font color="blue">pharmaceutical</font> company</font> and face all the <font color="blue">risks inherent</font> in     the <font color="blue">implementation</font> of a new business strategy</td>
    </tr>
    <tr>
      <td>In <font color="blue">conjunction with</font> the sale of our prenatal and related <font color="blue">product lines</font>     and the grant of an exclusive <font color="blue">North American </font>license to our <font color="blue">lead product</font>     ESTRASORB, we have changed the focus of the <font color="blue">company from</font> the <font color="blue">development</font> and     <font color="blue">commercialization</font> of <font color="blue">specialty <font color="blue">pharmaceutical</font> products</font> to the research and     <font color="blue">development</font>  of  new  <font color="blue">products using</font> our <font color="blue"><font color="blue">proprietary</font> <font color="blue">drug delivery</font></font> and     <font color="blue">biological platforms</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict whether</font> we will be successful in     <font color="blue">implementing</font> our new business strategy</td>
    </tr>
    <tr>
      <td>We intend to focus our research and <font color="blue">development</font> <font color="blue">activities</font> on areas in     which  we  have  particular  strengths and <font color="blue">on <font color="blue">technologies</font></font> that appear     promising</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">technologies</font> often</font> are on the <font color="blue">cutting edge</font> of modern     science</td>
    </tr>
    <tr>
      <td>As a result, the outcome of any research or <font color="blue">development</font> program is     <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>Only a very small fraction of these programs ultimately     result in commercial products or even product <font color="blue">candidates</font> and a number of     <font color="blue">events <font color="blue">could delay</font></font> our <font color="blue">development</font> efforts and <font color="blue"><font color="blue">negatively</font> impact</font> our ability     to  obtain  <font color="blue"><font color="blue">regulatory</font> approval</font> for, and to market and sell, a product     candidate</td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> that initially appear <font color="blue">promising often fail</font> to     <font color="blue">yield successful products</font></td>
    </tr>
    <tr>
      <td>In many cases, preclinical or <font color="blue">clinical studies</font>     will show that a <font color="blue">product candidate</font> is not <font color="blue">efficacious</font>, or that it raises     safety  concerns  or has other side effects that outweigh the intended     benefit</td>
    </tr>
    <tr>
      <td>Further, success in clinical     trials  will  <font color="blue">likely lead</font> to increased <font color="blue">investment</font>, <font color="blue">adversely</font> affecting     short-term <font color="blue">profitability</font>, to <font color="blue">bring <font color="blue">such products</font></font> to market</td>
    </tr>
    <tr>
      <td>Even after a     product is approved and launched, general usage or post-marketing studies     may identify safety or other <font color="blue"><font color="blue">previously unknown</font> <font color="blue">problems with</font></font> the product,     which may result in <font color="blue"><font color="blue">regulatory</font> approval</font>s being suspended, limited to narrow     <font color="blue">indications</font>  or  revoked,  or  which  <font color="blue">may otherwise prevent successful</font>     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We must identify products and product <font color="blue">candidates</font> for <font color="blue">development</font> with     our  <font color="blue">technologies</font>  and <font color="blue">establish successful <font color="blue">government</font></font> and third-party     <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>Our long-term ability to generate product-related revenue depends in     part on our ability to identify products and product <font color="blue">candidates</font> that may     utilize our <font color="blue">drug delivery</font> and biological <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">internal efforts</font>     do not generate sufficient product <font color="blue">candidates</font>, we will need to identify     <font color="blue">third parties</font> that wish to license our <font color="blue">technologies</font> for <font color="blue">development</font> of their     products or product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may be unable to license our <font color="blue">technologies</font>     to <font color="blue">third parties</font> for a number of reasons, including:       •   an <font color="blue">inability</font> to <font color="blue">negotiate license terms</font> that <font color="blue">would allow us</font> to make an     <font color="blue">appropriate return from</font> resulting products;         •   an <font color="blue">inability</font> to identify <font color="blue">suitable products</font> or product <font color="blue">candidates</font>     within, or <font color="blue">complementary</font> to, our areas of expertise; or          •     an  <font color="blue">unwillingness</font>  on  the part of <font color="blue">competitors</font> to utilize the     <font color="blue">technologies</font> of a <font color="blue">competing company</font> or disclose the existence or status of     <font color="blue">new products</font> or products <font color="blue">candidates</font> under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our  near and long-term viability will also depend in part on our     ability  to  <font color="blue">successfully</font>  <font color="blue">establish new <font color="blue">strategic <font color="blue">collaborations</font></font> with</font>     <font color="blue">pharmaceutical</font>  and  <font color="blue">bio<font color="blue">technology</font></font>  companies and <font color="blue"><font color="blue">government</font> agencies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Establishing </font><font color="blue">strategic <font color="blue">collaborations</font></font> and obtaining <font color="blue"><font color="blue">government</font> funding</font> are     <font color="blue">difficult</font>  and  time-consuming</td>
    </tr>
    <tr>
      <td><font color="blue">Potential  </font><font color="blue">collaborators</font>  may  reject     <font color="blue"><font color="blue">collaborations</font> based upon</font> their <font color="blue">assessment</font> of our financial, <font color="blue">regulatory</font> or     <font color="blue">intellectual</font> property position; <font color="blue"><font color="blue">government</font> agencies</font> may reject contract or     <font color="blue">grant <font color="blue">applications</font> based on</font> their <font color="blue">assessment</font> of public need, the public     interest and our products’ ability to address these areas</td>
    </tr>
    <tr>
      <td>If we fail to     establish a sufficient number of <font color="blue">collaborations</font> or <font color="blue">government</font> <font color="blue">relationships</font>     on acceptable terms, we may not <font color="blue">generate sufficient revenue</font></td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________                Even  if  we  <font color="blue">successfully</font> establish new <font color="blue">collaborations</font> or obtain     <font color="blue"><font color="blue">government</font> funding</font>, these <font color="blue">relationships</font> may never result in the successful     <font color="blue">development</font> or <font color="blue">commercialization</font> of any product <font color="blue">candidates</font> or the <font color="blue">generation</font>     of any sales or <font color="blue">royalty revenue</font></td>
    </tr>
    <tr>
      <td>Reliance on such <font color="blue">relationships</font> also exposes     us  to  a  number of risks</td>
    </tr>
    <tr>
      <td>We may not have the ability to control the     <font color="blue">activities</font> of our partners and <font color="blue">cannot assure</font> you that they will fulfill     their <font color="blue">obligations</font> to us, including <font color="blue">with respect</font> to the license, <font color="blue">development</font>     and <font color="blue">commercialization</font> of products and product <font color="blue">candidates</font>, in a <font color="blue">timely manner</font>     or at all</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that such <font color="blue">partners will</font> devote sufficient     resources to our products and product <font color="blue">candidates</font> or properly maintain or     defend our <font color="blue"><font color="blue">intellectual</font> property rights</font>; we also can <font color="blue">give <font color="blue">no assurances</font></font> that     our <font color="blue">partners will</font> not <font color="blue">utilize <font color="blue">such rights</font></font> in such a way as to invite or     cause <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure on</font> the part of our partners to perform or     satisfy their <font color="blue">obligations</font> to <font color="blue">us could lead</font> to delays in the <font color="blue">development</font> or     <font color="blue">commercialization</font> of products and product <font color="blue">candidates</font>, and affect our ability     to realize <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>Dis<font color="blue"><font color="blue">agreement</font>s</font>, including <font color="blue">disputes over</font> the     ownership of <font color="blue">technology</font> developed with such <font color="blue">collaborators</font>, could result in     <font color="blue">litigation</font>, which would be time-consuming and expensive, and may delay or     terminate  research and <font color="blue">development</font> efforts, <font color="blue"><font color="blue">regulatory</font> approval</font>s, and     <font color="blue">commercialization</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">partners fail</font> to maintain our     <font color="blue">existing <font color="blue"><font color="blue">agreement</font>s</font></font> or in the event we fail to <font color="blue">establish <font color="blue"><font color="blue">agreement</font>s</font> as</font>     <font color="blue">necessary</font>,  we  could  be required to undertake research, <font color="blue">development</font>,     <font color="blue">manufacturing</font> and <font color="blue">commercialization</font> <font color="blue">activities</font> solely at our own expense</td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font> would <font color="blue"><font color="blue">significant</font>ly</font> increase our <font color="blue">capital <font color="blue">requirements</font></font> and,     given our current limited sales, marketing and <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font>,     <font color="blue"><font color="blue">significant</font>ly</font>  delay  the  <font color="blue">commercialization</font>  of  products and product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success <font color="blue">depends on</font></font> our ability to maintain the <font color="blue">proprietary</font> nature     of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our  success in large part <font color="blue">depends on</font> our ability to maintain the     <font color="blue">proprietary</font> nature of our <font color="blue">technology</font> and other <font color="blue">trade secrets</font>, including our     <font color="blue"><font color="blue">proprietary</font> <font color="blue">drug delivery</font></font> and biological <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>To do so, we must     prosecute and maintain <font color="blue">existing patents</font>, obtain <font color="blue">new patents</font> and pursue trade     secret and other <font color="blue"><font color="blue">intellectual</font> property protection</font></td>
    </tr>
    <tr>
      <td>We also must operate     <font color="blue">without infringing</font> the <font color="blue">proprietary</font> rights of <font color="blue">third parties</font> or <font color="blue">letting third</font>     parties  infringe  our  rights</td>
    </tr>
    <tr>
      <td>We currently have 57 US patents and     <font color="blue">corresponding</font>  foreign  patents  and  <font color="blue"><font color="blue">patent <font color="blue">applications</font></font> covering</font> our     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">patent issues</font> relating to <font color="blue">pharmaceutical</font>s involve     complex legal, scientific and factual questions</td>
    </tr>
    <tr>
      <td>To date, no consistent     policy has emerged regarding the breadth of <font color="blue">bio<font color="blue">technology</font></font> patent claims that     are <font color="blue">granted by</font> the <font color="blue">US Patent and Trademark Office </font>or <font color="blue">enforced by</font> the     federal courts</td>
    </tr>
    <tr>
      <td>Therefore, we do not know whether our <font color="blue">patent <font color="blue">applications</font></font>     will result in the issuance of patents, or that any <font color="blue">patents issued</font> to us     <font color="blue">will <font color="blue">provide us with</font></font> any <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be sure that     we  will  develop <font color="blue">additional</font> <font color="blue">proprietary</font> products that are patentable</td>
    </tr>
    <tr>
      <td>Furthermore, there is a risk that <font color="blue">others will independently</font> develop or     duplicate similar <font color="blue">technology</font> or products or <font color="blue">circumvent</font> the <font color="blue">patents issued</font> to     us</td>
    </tr>
    <tr>
      <td>There is a risk that <font color="blue">third parties</font> may challenge our <font color="blue">existing patents</font>     or claim that we are infringing their patents or <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>We     <font color="blue">could incur</font> substantial costs in <font color="blue">defending patent <font color="blue">infringement</font> suits</font> or in     <font color="blue">filing suits against others</font> to have their patents declared invalid or claim     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that we may be required to obtain licenses     from  third  parties  to avoid infringing third-party patents or other     <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>We cannot be sure that such third-party licenses would     be available to us on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If we are unable to     obtain required third-party licenses, we may be delayed in or prohibited     from developing, <font color="blue">manufacturing</font> or <font color="blue">selling products</font> requiring <font color="blue">such licenses</font></td>
    </tr>
    <tr>
      <td>Although our patents include claims <font color="blue">covering various</font> features of our     products  and  product  <font color="blue">candidates</font>,  including <font color="blue">composition</font>, methods of     <font color="blue">manufacture</font> and use, our patents do not <font color="blue">provide us with</font> complete protection     against the <font color="blue">development</font> of <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>Some of our know-how and     <font color="blue">technology</font>  is  not  patentable</td>
    </tr>
    <tr>
      <td>To protect our <font color="blue">proprietary</font> rights in     <font color="blue">unpatentable <font color="blue">intellectual</font> property</font> and <font color="blue">trade secrets</font>, we require employees,     <font color="blue">consultants</font>,  advisors and <font color="blue">collaborators</font> to <font color="blue">enter into confidentiality</font>     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> may not <font color="blue">provide meaningful protection</font> for our     <font color="blue">trade secrets</font>, know-how or other <font color="blue">proprietary</font> information in the event of any     <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">financial resources</font> and we are not certain that we will     be  able to obtain financing to maintain our <font color="blue">operations</font> or to fund the     <font color="blue">development</font> of <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Over the next few years we may not <font color="blue">generate revenues</font> from product     sales, licensing fees, royalties, <font color="blue">milestones</font>, contract research and other     sources  in  an  <font color="blue">amount sufficient</font> to fund our <font color="blue">operations</font>, and we will     <font color="blue">therefore use</font> our <font color="blue">cash resources</font> and could require <font color="blue"><font color="blue">additional</font> funds</font> to     maintain our <font color="blue">operations</font>, continue our research and <font color="blue">development</font> programs,     <font color="blue">commence future preclinical</font> and <font color="blue">clinical trials</font>, seek <font color="blue"><font color="blue">regulatory</font> approval</font>s     and market our products</td>
    </tr>
    <tr>
      <td>We will seek such <font color="blue"><font color="blue">additional</font> funds</font> through public     or <font color="blue">private equity</font> or debt financings, <font color="blue">collaborative</font> <font color="blue">arrangements</font> and other     sources</td>
    </tr>
    <tr>
      <td>We cannot be certain that <font color="blue">adequate <font color="blue">additional</font> funding will</font> be     available to us on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot raise</font> the     <font color="blue"><font color="blue">additional</font> funds</font> required for our anticipated <font color="blue">operations</font>, we may be required     to delay <font color="blue"><font color="blue">significant</font>ly</font>, reduce the scope of or <font color="blue">eliminate one</font> or more of our     research or <font color="blue">development</font> programs, downsize our general and <font color="blue">administrative</font>     <font color="blue">infrastructure</font>  or  programs,  or  seek  <font color="blue">alternative measures</font> to avoid     <font color="blue">insolvency</font>, including <font color="blue"><font color="blue">arrangements</font> with <font color="blue">collaborative</font> partners</font> or others     that may require us to <font color="blue">relinquish rights</font> to certain of our <font color="blue">technologies</font>,     product <font color="blue">candidates</font> or products</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue"><font color="blue">additional</font> funds</font> through future     offerings of shares of our <font color="blue">common stock</font> or other securities, such offerings     would cause dilution of existing <font color="blue">stockholders</font>’ percentage ownership in the     company</td>
    </tr>
    <tr>
      <td>These <font color="blue">future offerings also could</font> have a material and adverse     effect on the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________                We have a history of losses and our <font color="blue">future <font color="blue">profitability</font></font> is uncertain</td>
    </tr>
    <tr>
      <td>Our expenses have exceeded our <font color="blue">revenues since</font> our formation in 1987,     and our <font color="blue">accumulated deficit at</font> <font color="blue">December </font>31, 2005 was dlra141dtta9 million</td>
    </tr>
    <tr>
      <td>Our net     revenues for the <font color="blue">last three years</font> were dlra7dtta4 million in 2005, dlra8dtta3 million in     2004  and  dlra11dtta8 million in 2003</td>
    </tr>
    <tr>
      <td>We have received a limited amount of     product-related revenue <font color="blue">from research</font> contracts, licenses and <font color="blue"><font color="blue">agreement</font>s</font> to     provide vaccine products, services and adjuvant <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We cannot be     certain that we will be successful in <font color="blue">entering into strategic alliances</font> or     <font color="blue"><font color="blue">collaborative</font> <font color="blue">arrangements</font> with</font> other companies that will result in other     <font color="blue"><font color="blue">significant</font> revenues</font> to offset our expenses</td>
    </tr>
    <tr>
      <td>Our losses have resulted <font color="blue">from research</font> and <font color="blue">development</font> expenses, sales     and  marketing  expenses for ESTRASORB, protection of our <font color="blue">intellectual</font>     property and other general operating expenses</td>
    </tr>
    <tr>
      <td>Our <font color="blue">losses increased due</font> to     the launch of <font color="blue">ESTRASORB </font>as we expanded our <font color="blue">manufacturing</font> <font color="blue">capacity</font> and sales     and  marketing  <font color="blue">capabilities</font>,  and <font color="blue">may increase as</font> and when we conduct     <font color="blue">additional</font> and <font color="blue">larger <font color="blue">clinical trials</font></font> for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Therefore,     we expect our cumulative operating loss to <font color="blue">increase until such</font> time, if     ever,  product  sales, licensing fees, royalties, <font color="blue">milestones</font>, contract     research  and  other  sources  <font color="blue">generate sufficient revenue</font> to fund our     continuing <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We cannot predict when, if ever, we might achieve     <font color="blue">profitability</font>  and  cannot  be certain that we will be able to sustain     <font color="blue">profitability</font>, if achieved</td>
    </tr>
    <tr>
      <td>Many  of our <font color="blue">competitors</font> have <font color="blue"><font color="blue">significant</font>ly</font> greater resources and     experience, which may <font color="blue"><font color="blue">negatively</font> impact</font> our commercial <font color="blue">opportunities</font> and     those of our current and future licensees</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font> industries are subject to intense     <font color="blue">competition</font> and rapid and <font color="blue"><font color="blue">significant</font> technological</font> change</td>
    </tr>
    <tr>
      <td>We have many     potential  <font color="blue">competitors</font>,  including  <font color="blue">major drug</font> and <font color="blue">chemical companies</font>,     specialized <font color="blue">bio<font color="blue">technology</font></font> firms, academic <font color="blue">institutions</font>, <font color="blue"><font color="blue">government</font> agencies</font>     and private and <font color="blue">public research <font color="blue">institutions</font></font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have     <font color="blue"><font color="blue">significant</font>ly</font> greater financial and technical resources, experience and     expertise in:       •   research and <font color="blue">development</font>;         •   pre-clinical testing;         •   <font color="blue">clinical trials</font>;         •   <font color="blue">regulatory</font> processes and approvals;         •   production and <font color="blue">manufacturing</font>; and         •   sales and marketing of <font color="blue">approved products</font></td>
    </tr>
    <tr>
      <td>and MedImmune Inc, among others, compete     in  the  vaccine  market</td>
    </tr>
    <tr>
      <td>In particular, these companies have greater     experience and expertise in <font color="blue">securing <font color="blue">government</font> contracts</font> and grants to     support their research and <font color="blue">development</font> efforts, conducting testing and     trials, obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s to <font color="blue">market products</font>, and <font color="blue">manufacturing</font>     <font color="blue">such <font color="blue">products on</font></font> a <font color="blue">broad scale</font></td>
    </tr>
    <tr>
      <td>Smaller or early-stage companies and research <font color="blue">institutions</font> may also     prove to be <font color="blue">significant</font> <font color="blue">competitors</font>, <font color="blue">particularly</font> through <font color="blue">collaborative</font>     <font color="blue">arrangements</font> with large and established <font color="blue">pharmaceutical</font> or other companies</td>
    </tr>
    <tr>
      <td>We will also face <font color="blue">competition</font> from these parties in recruiting and retaining     <font color="blue">qualified scientific</font> and management personnel, establishing clinical trial     sites and <font color="blue">patient registration</font> for <font color="blue">clinical trials</font>, and in acquiring and     in-licensing <font color="blue">technologies</font> and products <font color="blue">complementary</font> to our programs or     <font color="blue"><font color="blue">potentially</font> advantageous</font> to our business</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">competitors</font> succeeds     in obtaining <font color="blue">approval from</font> the FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font> for their     products sooner than we do or for products that are more <font color="blue">effective</font> or less     <font color="blue">costly than ours</font>, our <font color="blue">commercial <font color="blue">opportunity</font> could</font> be <font color="blue"><font color="blue">significant</font>ly</font> reduced</td>
    </tr>
    <tr>
      <td>In order to <font color="blue">effective</font>ly compete, we will have to make substantial     <font color="blue"><font color="blue">investment</font>s</font> in sales and marketing or <font color="blue">partner with one</font> or more established     companies</td>
    </tr>
    <tr>
      <td>There is no assurance that we will be successful in gaining     <font color="blue">significant</font>  market  share  for  any product or <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">technologies</font> and <font color="blue">products also may</font> be rendered obsolete or <font color="blue">non<font color="blue">competitive</font> as</font>     a result of <font color="blue">products introduced by</font> our <font color="blue">competitors</font> to the marketplace more     rapidly and at a <font color="blue">lower cost</font></td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________                The return on our <font color="blue">investment</font> in <font color="blue">ESTRASORB </font>depends in large part on the     success of our <font color="blue">relationship with</font> Esprit and our ability to <font color="blue">manufacture</font> the     product</td>
    </tr>
    <tr>
      <td>In October 2005, we <font color="blue">entered into</font> a License Agreement and a Supply     Agreement with Esprit Pharma for <font color="blue">ESTRASORB </font>Under the License Agreement, we     granted Esprit <font color="blue">exclusive rights</font> to market <font color="blue">ESTRASORB </font>in North America</td>
    </tr>
    <tr>
      <td>In     <font color="blue">consideration</font> for <font color="blue">such rights</font>, Esprit will pay dlra12dtta5 million within the     first year as well as sales-based milestone payments, and Novavax also is     entitled to receive a <font color="blue">royalty on</font> all <font color="blue">future net sales</font> of <font color="blue">ESTRASORB </font>         While  our  License  Agreement  with Esprit gives us some limited     protections <font color="blue">with respect</font> to that company’s <font color="blue">ESTRASORB </font>marketing and sales     efforts and, we believe, creates <font color="blue">incentives</font> for Esprit <font color="blue">consistent with</font> our     own, we <font color="blue">cannot control</font> the amount and timing of the <font color="blue">marketing efforts</font> that     Esprit devotes to <font color="blue">ESTRASORB </font>or make any assurances that Esprit’s promotion     and marketing of <font color="blue">ESTRASORB </font>in North America will be successful</td>
    </tr>
    <tr>
      <td>We do not     have  a history of working <font color="blue">together with</font> Esprit and cannot predict the     success of the collaboration, nor can we give any assurances that Esprit     will  not reduce or curtail its efforts to market <font color="blue">ESTRASORB </font>because of     <font color="blue">factors affecting</font> its business or <font color="blue">operations</font> beyond our control</td>
    </tr>
    <tr>
      <td>Any loss of     Esprit as a partner in the <font color="blue">commercialization</font> of ESTRASORB, <font color="blue">dispute over</font> the     terms of or <font color="blue">decisions</font> regarding the License and Supply Agreements, or other     adverse <font color="blue">development</font>s in our <font color="blue">relationship with</font> Esprit may harm our business     and <font color="blue">might accelerate</font> our need for <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>We also can give no     assurances that Esprit will be more <font color="blue">successful than</font> Novavax in gaining     market <font color="blue">acceptance</font> of <font color="blue">ESTRASORB </font>Prescription trends for <font color="blue">ESTRASORB </font>have not     met our <font color="blue">expectations</font> to date and Esprit will face similar obstacles to     <font color="blue">gaining market</font> share of the <font color="blue">estrogen therapy market</font>, including <font color="blue">competition</font>     from large and <font color="blue">established companies with</font> similar <font color="blue">estrogen therapy products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Numerous  </font><font color="blue">companies worldwide currently</font> produce and <font color="blue">sell estrogen</font>     products  for  clinical  <font color="blue">indications</font> identical to those for <font color="blue">ESTRASORB </font>    Currently, the oral and patch product segments account for <font color="blue">approximately</font> 75prca     and 15prca of the market, respectively, according to 2004 Verispan data</td>
    </tr>
    <tr>
      <td><font color="blue">Wyeth     </font>commits <font color="blue">significant</font> resources to the sale and marketing of its product,     Premarin^^®, in order to maintain its market <font color="blue">leadership</font> position</td>
    </tr>
    <tr>
      <td><font color="blue">Several     </font>other  companies  compete  in  the  estrogen category including Berlex     Laboratories,  Inc, Novartis Pharma AG and Solvay Pharmaceuticals</td>
    </tr>
    <tr>
      <td>In     particular, Solvay has introduced an alcohol-based gel product, Estrogel,     which is <font color="blue">directly <font color="blue">competitive</font> with</font> <font color="blue">ESTRASORB </font>These and other <font color="blue">products sold</font>     by our <font color="blue">competitors</font> have all achieved a degree of <font color="blue">market penetration</font> superior     to <font color="blue">ESTRASORB </font>         In addition, under the Supply Agreement, we are obligated to supply     Esprit  with  <font color="blue">ESTRASORB </font> through the <font color="blue">manufacture</font> of the <font color="blue">product at</font> our     <font color="blue">manufacturing</font> <font color="blue">facility</font> in Philadelphia, Pennsylvania</td>
    </tr>
    <tr>
      <td>We have only limited     experience with the large <font color="blue">capacity</font> <font color="blue">manufacturing</font> required for the commercial     sale of a product</td>
    </tr>
    <tr>
      <td>Although we have validated our <font color="blue">manufacturing</font> methods for     the <font color="blue">product with</font> the FDA, we will remain subject to that agency’s rules and     <font color="blue">regulations</font> regarding good <font color="blue">manufacturing</font> practices, which are <font color="blue">enforced by</font>     the FDA through its <font color="blue">facilities inspection program</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with such     rules and <font color="blue">regulations</font> requires us to spend substantial funds and hire and     retain <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We face the <font color="blue">possibility</font> that we may not be able     to meet Esprit’s <font color="blue">supply <font color="blue">requirements</font> under</font> the <font color="blue">agreement</font> in a <font color="blue">timely fashion</font>     at acceptable quality, quantity and prices or in <font color="blue">compliance with applicable</font>     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">facility</font> fails</font> to <font color="blue">comply with</font> applicable <font color="blue">regulations</font>, we     will  be forced to utilize a <font color="blue"><font color="blue">third party</font> contractor</font> to <font color="blue">manufacture</font> the     product</td>
    </tr>
    <tr>
      <td>We  may  not be able to enter into alternative <font color="blue">manufacturing</font>     <font color="blue">arrangements</font> at commercially acceptable rates, if at all</td>
    </tr>
    <tr>
      <td>Moreover, the     <font color="blue">manufacture</font>rs we use may not provide <font color="blue">sufficient quantities</font> of product to     meet our <font color="blue">specifications</font> or our delivery, cost and other <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">must utilize</font> our <font color="blue">manufacturing</font> <font color="blue">facility</font> for products other than     <font color="blue">ESTRASORB </font>in order to avoid operating the <font color="blue">facility</font> at a loss</td>
    </tr>
    <tr>
      <td><font color="blue">Currently  </font>we  are  <font color="blue">manufacturing</font>  <font color="blue">ESTRASORB </font> at  our <font color="blue">facility</font> in     <font color="blue">Philadelphia </font>and will <font color="blue">manufacture</font> the <font color="blue">product at</font> a loss until production     volumes  increase  or  we enter into <font color="blue">additional</font> contract <font color="blue">manufacturing</font>     <font color="blue">arrangements</font>  with  <font color="blue">third parties</font> to more fully utilize the <font color="blue">facility</font>’s     <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">facility</font> is able to <font color="blue">accommodate</font> a much <font color="blue">greater production</font>     <font color="blue">schedule than</font> its <font color="blue">currently schedule</font>, and offset the fixed costs related to     the <font color="blue">manufacturing</font> process and <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Until we <font color="blue">increase production</font> of     <font color="blue">ESTRASORB </font> or  enter into such contract <font color="blue">manufacturing</font> <font color="blue">arrangements</font> for     <font color="blue">sufficient quantities</font>, the cost of <font color="blue">products sold</font> <font color="blue">percentages</font> will continue     to be unusually high and we will continue to <font color="blue">manufacture</font> the <font color="blue">product at</font> a     loss</td>
    </tr>
    <tr>
      <td>In  addition, while the company was successful in <font color="blue">negotiating</font> a     substantial reduction in its <font color="blue">monthly rent</font> for the <font color="blue">facility</font> during 2005, such     <font color="blue">reductions will</font> expire in the summer of 2006 and the company expects lease     costs to increase, <font color="blue">potentially</font> by a material amount</td>
    </tr>
    <tr>
      <td>Although we are working     to <font color="blue">design alternative packaging solutions</font> to <font color="blue">further streamline production</font>     and <font color="blue">lower cost</font>s of production, there can be <font color="blue">no assurances</font> that <font color="blue">such efforts</font>     will result in <font color="blue">meaningful cost savings</font> or otherwise be successful</td>
    </tr>
    <tr>
      <td>13       _________________________________________________________________                We have not completed the <font color="blue">development</font> of products other than <font color="blue">ESTRASORB </font>    and we may not succeed in obtaining the FDA approval <font color="blue">necessary</font> to sell     <font color="blue">additional</font> products</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, <font color="blue">manufacture</font> and marketing of our <font color="blue">pharmaceutical</font> and     <font color="blue">biological products</font> are subject to <font color="blue"><font color="blue">government</font> regulation</font> in the United     States and other countries</td>
    </tr>
    <tr>
      <td><font color="blue">In the <font color="blue">United States</font> </font>and most foreign countries,     we must complete rigorous preclinical testing and extensive human clinical     trials that <font color="blue">demonstrate</font> the safety and efficacy of a product in order to     apply for <font color="blue"><font color="blue">regulatory</font> approval</font> to market the product</td>
    </tr>
    <tr>
      <td><font color="blue">ESTRASORB </font>is the only     product developed by the company to have <font color="blue">been approved</font> for sale in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Approval outside the US may take longer or may require     <font color="blue">additional</font> <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">product candidate</font> <font color="blue">ANDROSORB </font>has completed     Phase  I  human <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>product <font color="blue">candidates</font> are in     <font color="blue">preclinical <font color="blue">laboratory</font></font> or <font color="blue">animal studies</font></td>
    </tr>
    <tr>
      <td>Before  applying  for FDA approval to market any <font color="blue">new drug product</font>     <font color="blue">candidates</font>, we <font color="blue">must first submit</font> an IND that explains to the FDA the results     of pre-clinical testing conducted in <font color="blue">laboratory</font> animals and what we propose     to  do for <font color="blue">human testing</font></td>
    </tr>
    <tr>
      <td>At this stage, the FDA <font color="blue">decides whether</font> it is     <font color="blue">reasonably safe</font> to move <font color="blue">forward with testing</font> the <font color="blue">drug on humans</font></td>
    </tr>
    <tr>
      <td>We must     then  conduct  Phase I studies and larger-scale <font color="blue">Phase II and III </font>human     <font color="blue">clinical trials</font> that <font color="blue">demonstrate</font> the safety and efficacy of our products to     the <font color="blue">satisfaction</font> of the FDA Once these trials are complete, an NDA can be     <font color="blue">filed with</font> the FDA <font color="blue">requesting approval</font> of the drug for marketing</td>
    </tr>
    <tr>
      <td>Vaccine clinical <font color="blue">development</font> follows the <font color="blue">same general pathway as</font> for     drugs and other biologics</td>
    </tr>
    <tr>
      <td>A sponsor who wishes to begin <font color="blue">clinical trials</font>     with a vaccine must submit an IND <font color="blue">describing</font> the vaccine, its method of     <font color="blue">manufacture</font>  and  quality  control  tests  for  release</td>
    </tr>
    <tr>
      <td>Pre-marketing     (pre-licensure) vaccine <font color="blue">clinical trials</font> are <font color="blue">typically done</font> in <font color="blue">three phases</font></td>
    </tr>
    <tr>
      <td>Initial human studies, referred to as Phase I, are safety and <font color="blue">immunogenicity</font>     studies performed in a small number of <font color="blue">closely monitored subjects</font></td>
    </tr>
    <tr>
      <td><font color="blue">Phase II     </font>studies  are dose-ranging studies and <font color="blue">may enroll hundreds</font> of subjects</td>
    </tr>
    <tr>
      <td>Finally, Phase III <font color="blue">trials typically enroll thousands</font> of <font color="blue">individuals</font> and     provide the <font color="blue">critical documentation</font> of <font color="blue">effective</font>ness and important <font color="blue">additional</font>     <font color="blue">safety data</font> required for licensing</td>
    </tr>
    <tr>
      <td>If  successful,  the  <font color="blue">completion</font>  of all <font color="blue">three phases</font> of clinical     <font color="blue">development</font>  can  be <font color="blue">followed by</font> the submission of a Biologics License     Application</td>
    </tr>
    <tr>
      <td>Also during this stage, the proposed <font color="blue">manufacturing</font> <font color="blue">facility</font>     undergoes a pre-approval inspection during which production of the vaccine     as it is in progress is examined in detail</td>
    </tr>
    <tr>
      <td>Vaccine <font color="blue">approval also</font> requires     the provision of <font color="blue">adequate product labeling</font> to <font color="blue">allow health care providers</font> to     understand the vaccine’s proper use, including its <font color="blue">potential benefits</font> and     risks, to communicate <font color="blue">with patients</font> and parents, and to safely deliver the     vaccine to the public</td>
    </tr>
    <tr>
      <td>Until a vaccine is given to the <font color="blue">general population</font>,     all <font color="blue">potential <font color="blue">adverse event</font>s cannot</font> be anticipated</td>
    </tr>
    <tr>
      <td>Thus, many vaccines     undergo <font color="blue">Phase IV </font>studies after a BLA has <font color="blue">been approved</font> and the vaccine is     licensed and on the market</td>
    </tr>
    <tr>
      <td>These processes are expensive and can take many years to complete, and     we may not be able to <font color="blue">demonstrate</font> the safety and efficacy of our products to     the <font color="blue">satisfaction</font> of such <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue"><font color="blue">authorities</font> may</font>     also require <font color="blue">additional</font> testing and we may be required to <font color="blue">demonstrate</font> that     our <font color="blue">proposed products represent</font> an improved form of <font color="blue">treatment over existing</font>     therapies,  which we may be unable to do so <font color="blue">without conducting further</font>     <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>Moreover, if the FDA grants <font color="blue"><font color="blue">regulatory</font> approval</font> of a     product, the <font color="blue">approval may</font> be limited to specific <font color="blue">indications</font> or limited with     respect to its <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Expanded or <font color="blue">additional</font> <font color="blue">indications</font> for approved     drugs  may  not  be  approved, which <font color="blue">could limit</font> our revenues</td>
    </tr>
    <tr>
      <td><font color="blue">Foreign     </font><font color="blue">regulatory</font> <font color="blue"><font color="blue">authorities</font> may</font> apply similar <font color="blue">limitations</font> or may refuse to grant     any approval</td>
    </tr>
    <tr>
      <td>Consequently, even if we believe that preclinical and clinical     data  are  sufficient  to  support <font color="blue"><font color="blue">regulatory</font> approval</font> for our product     <font color="blue">candidates</font>, the FDA and foreign <font color="blue">regulatory</font> <font color="blue"><font color="blue">authorities</font> may</font> not ultimately     grant  approval  for  commercial sale in any <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>If our drug     <font color="blue">candidates</font> are not approved, our ability to <font color="blue"><font color="blue">generate revenues</font> may</font> be limited     and our business will be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We may fail to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">products on</font> a timely     basis or <font color="blue">comply with</font> our continuing <font color="blue">regulatory</font> <font color="blue">obligations</font> after approval is     obtained</td>
    </tr>
    <tr>
      <td>Delays in obtaining <font color="blue"><font color="blue">regulatory</font> approval</font> can be extremely costly in     terms of lost sales <font color="blue">opportunities</font> and increased clinical trial costs</td>
    </tr>
    <tr>
      <td>The     <font color="blue">speed with which</font> we complete our <font color="blue">clinical trials</font> and our <font color="blue">applications</font> for     <font color="blue">marketing approval will depend on several factors</font>, including the following:       •   the rate of <font color="blue">patient enrollment</font> and retention, which is a function of     many factors, including the size of the <font color="blue">patient population</font>, the proximity of     patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the study and the     nature of the protocol;         •   <font color="blue">Institutional Review Board </font>approval of the protocol and the informed     consent form;         •   prior <font color="blue">regulatory</font> agency review and approval;          •     our ability to <font color="blue">manufacture</font> or obtain <font color="blue">sufficient quantities</font> of     materials for use in <font color="blue">clinical trials</font>;                                         14       _________________________________________________________________             •   <font color="blue">negative test</font> results or side effects experienced by trial     <font color="blue">participants</font>;         •   analysis of data obtained <font color="blue">from preclinical</font> and clinical <font color="blue">activities</font>,     which are susceptible to <font color="blue">varying interpretations</font> and <font color="blue">which interpretations</font>     <font color="blue">could delay</font>, limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font>;         •   changes in the policies of <font color="blue">regulatory</font> <font color="blue">authorities</font> for drug or vaccine     <font color="blue">approval during</font> the period of product <font color="blue">development</font>; and         •   the <font color="blue">availability</font> of skilled and experienced staff to conduct and     monitor  clinical  studies  and  to prepare the appropriate <font color="blue">regulatory</font>     <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>We have limited experience in conducting and managing the preclinical     and <font color="blue">clinical trials</font> <font color="blue">necessary</font> to obtain <font color="blue">regulatory</font> marketing approvals</td>
    </tr>
    <tr>
      <td>We     may  not be able to obtain the approvals <font color="blue">necessary</font> to <font color="blue">conduct clinical</font>     studies</td>
    </tr>
    <tr>
      <td>We also face the risk that the results of our <font color="blue">clinical trials</font> may     be in<font color="blue">consistent with</font> the results obtained in pre<font color="blue">clinical studies</font> or that the     results obtained in <font color="blue">later phases</font> of <font color="blue">clinical trials</font> may be in<font color="blue">consistent with</font>     those obtained in <font color="blue">earlier phases</font></td>
    </tr>
    <tr>
      <td>A number of companies in the specialty     bio<font color="blue">pharmaceutical</font> and product <font color="blue">development</font> industry have suffered <font color="blue">significant</font>     setbacks in advanced <font color="blue">clinical trials</font>, even after experiencing promising     results in <font color="blue">early animal</font> and <font color="blue">human testing</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">regulatory</font> approval</font> of a drug     is granted, such approval is likely to limit the <font color="blue">indicated uses</font> for which it     may be marketed</td>
    </tr>
    <tr>
      <td>Furthermore, even if a product gains <font color="blue"><font color="blue">regulatory</font> approval</font>, the product     and the <font color="blue">manufacture</font>r of the <font color="blue">product will</font> be subject to continuing <font color="blue">regulatory</font>     review, including <font color="blue">adverse event</font> reporting <font color="blue">requirements</font> and the FDA’s general     <font color="blue">prohibition against promoting products</font> for <font color="blue">unapproved uses</font></td>
    </tr>
    <tr>
      <td>Failure to     <font color="blue">comply with</font> any post-approval <font color="blue">requirements</font> can, among other things, result     in  warning  letters,  product  seizures, recalls, fines, <font color="blue">injunctions</font>,     <font color="blue">suspensions</font> or <font color="blue">revocations</font> of marketing licenses, operating <font color="blue">restrictions</font> and     criminal <font color="blue">prosecutions</font></td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">enforcement</font> actions, any <font color="blue">unanticipated</font>     changes  in  existing  <font color="blue">regulatory</font>  <font color="blue">requirements</font> or the adoption of new     <font color="blue">requirements</font>, or any <font color="blue">safety issues</font> that arise with any <font color="blue">approved products</font>,     <font color="blue">could <font color="blue">adversely</font> affect</font> our ability to <font color="blue">market products</font> and <font color="blue">generate revenues</font>     and <font color="blue">thus <font color="blue">adversely</font> affect</font> our ability to continue our business</td>
    </tr>
    <tr>
      <td>We also may be restricted or <font color="blue">prohibited from marketing</font> or <font color="blue">manufacturing</font>     a product, even after obtaining <font color="blue">product approval</font>, if <font color="blue">previously unknown</font>     <font color="blue">problems with</font> the product or its <font color="blue">manufacture</font> are <font color="blue">subsequently discovered</font> and     we <font color="blue">cannot assure</font> you that <font color="blue">newly discovered</font> or developed <font color="blue">safety issues</font> will     not arise following any <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>With the use of any drug by a     wide <font color="blue">patient population</font>, serious <font color="blue">adverse event</font>s may occur from time to time     that initially do not appear to relate to the drug itself, and only if the     <font color="blue">specific event</font> occurs with some <font color="blue">regularity over</font> a period of time does the     drug become suspect as having a <font color="blue">causal relationship</font> to the <font color="blue">adverse event</font></td>
    </tr>
    <tr>
      <td>Any  <font color="blue">safety issues</font> could cause us to suspend or <font color="blue">cease marketing</font> of our     <font color="blue">approved products</font>, possibly subject us to substantial <font color="blue">liabilities</font>, and     <font color="blue">adversely</font>  affect  our  ability to <font color="blue">generate revenues</font> and our financial     condition</td>
    </tr>
    <tr>
      <td>Our substantial <font color="blue">indebtedness</font> <font color="blue">could <font color="blue">adversely</font> affect</font> our <font color="blue">cash flow</font> and     <font color="blue">prevent us from</font> fulfilling our <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">December </font>31,  2005,  we  had dlra30dtta5 million of outstanding     <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>Our substantial amount of outstanding <font color="blue">indebtedness</font> could have     <font color="blue">significant</font> consequences</td>
    </tr>
    <tr>
      <td>For example, it:       •   <font color="blue">could increase</font> our <font color="blue">vulnerability</font> to <font color="blue">general adverse economic</font> and     <font color="blue">industry conditions</font>;         •   requires us to dedicate a substantial portion of our <font color="blue">cash flow</font> from     <font color="blue">operations</font>  to  service  payments  on  our  <font color="blue">indebtedness</font>, reducing the     <font color="blue">availability</font> of our <font color="blue">cash flow</font> to <font color="blue">fund future capital expenditures</font>, working     capital, execution of our growth strategy, research and <font color="blue">development</font> costs     and other general corporate <font color="blue">requirements</font>;         •   <font color="blue">could limit</font> our <font color="blue">flexibility</font> in planning for, or reacting to, changes     in  our business and the industry, which may place us at a <font color="blue">competitive</font>     disadvantage compared with <font color="blue">competitors</font> that have less <font color="blue">indebtedness</font>; and          •     <font color="blue">could limit</font> our ability to obtain <font color="blue"><font color="blue">additional</font> funds</font>, even when     <font color="blue">necessary</font> to maintain <font color="blue">adequate liquidity</font></td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">additional</font> <font color="blue">indebtedness</font> for various reasons, which would     increase the <font color="blue">risks associated with</font> our substantial leverage</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________           Health <font color="blue">care insurers</font> and other payors may not pay for our products or may     <font color="blue">impose limits on <font color="blue">reimbursement</font></font></td>
    </tr>
    <tr>
      <td>Our  ability  and  the  ability  of our licensees to <font color="blue">successfully</font>     <font color="blue">commercialize</font> <font color="blue">ESTRASORB </font>and <font color="blue">future products</font> will depend, in part, on the     extent to which <font color="blue">reimbursement</font> for <font color="blue">such products</font> will be available from     third-party  payors  such  as  Medicare,  Medicaid, <font color="blue">health maintenance</font>     organizations, health insurers and other public and <font color="blue">private payors</font></td>
    </tr>
    <tr>
      <td>If we     succeed  in <font color="blue">bringing products</font> to the market, we cannot be assured that     third-party payors will pay for <font color="blue">such products</font> or establish and maintain     <font color="blue">price levels sufficient</font> for <font color="blue">realization</font> of an <font color="blue">appropriate return on</font> our     <font color="blue">investment</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>For example, <font color="blue">ESTRASORB </font>currently is being     sold as an <font color="blue">outpatient prescription drug</font></td>
    </tr>
    <tr>
      <td>Medicare does not cover the costs     of most <font color="blue">outpatient prescription drug</font>s</td>
    </tr>
    <tr>
      <td>We expect that over time <font color="blue">ESTRASORB </font>    will be treated the same as other <font color="blue">estrogen therapy products</font> <font color="blue">with respect</font> to     <font color="blue">government</font> and third-party payor <font color="blue">reimbursement</font>, however, <font color="blue">additional</font> time is     required to increase the number of payors who <font color="blue">currently accept</font> our product     for <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">ESTRASORB </font>will receive     similar <font color="blue">reimbursement</font> treatment</td>
    </tr>
    <tr>
      <td>Many <font color="blue">health maintenance</font> organizations and other third-party payors use     formularies, or lists of drugs for <font color="blue">which coverage</font> is <font color="blue">provided under</font> a health     <font color="blue">care benefit</font> plan, to control the costs of <font color="blue">prescription drugs</font></td>
    </tr>
    <tr>
      <td>Each payor     that maintains a <font color="blue">drug formulary</font> makes its own <font color="blue">determination as</font> to whether a     <font color="blue">new drug will</font> be added to the formulary and <font color="blue">whether particular drugs</font> in a     <font color="blue">therapeutic</font> class will have <font color="blue"><font color="blue">preferred status</font> over</font> other drugs in the same     class</td>
    </tr>
    <tr>
      <td>This <font color="blue">determination often involves</font> an <font color="blue">assessment</font> of the clinical     <font color="blue">appropriateness</font> of the drug and, in some cases, the cost of the drug in     <font color="blue">comparison</font> to <font color="blue">alternative products</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">ESTRASORB </font>    or any of our <font color="blue">future products</font> will be added to payors’ formularies, that our     <font color="blue">products will</font> have <font color="blue">preferred status</font> to <font color="blue">alternative therapies</font>, or that the     formulary <font color="blue">decisions</font> will be conducted in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may also decide</font>     to <font color="blue">enter into discount</font> or formulary fee <font color="blue">arrangements</font> with payors, which     could result in us receiving lower or <font color="blue">discounted prices</font> for <font color="blue">ESTRASORB </font>or     <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>We may have <font color="blue"><font color="blue">product liability</font> exposure</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">administration</font> of drugs to humans, whether in <font color="blue">clinical trials</font> or     after <font color="blue">marketing clearances</font> are obtained, can result in <font color="blue">product liability</font>     claims</td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">product liability</font> <font color="blue">insurance coverage</font> in the total amount     of dlra10dtta0 million for claims arising from the use of our <font color="blue">currently marketed</font>     products and products in <font color="blue">clinical trials</font> prior to FDA approval</td>
    </tr>
    <tr>
      <td>Coverage is     becoming increasingly expensive, however, and we may not be able to maintain     <font color="blue">insurance at</font> a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be     able to maintain our <font color="blue">existing <font color="blue">insurance coverage</font></font> or obtain coverage for the     use of our other products in the future</td>
    </tr>
    <tr>
      <td>This <font color="blue">insurance coverage</font> and our     resources  may not be sufficient to satisfy <font color="blue">liabilities</font> resulting from     <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>A successful claim may <font color="blue">prevent us from</font> obtaining     adequate <font color="blue">product liability</font> insurance in the <font color="blue">future on commercially desirable</font>     terms, if at all</td>
    </tr>
    <tr>
      <td>Even if a claim is not successful, defending such a claim     would be time-consuming and expensive, may damage our reputation in the     marketplace, and would likely divert management’s attention</td>
    </tr>
    <tr>
      <td>We have made loans to certain of our <font color="blue">directors</font>, and have guaranteed a     brokerage  margin  loan for one of these <font color="blue">directors</font>, which could have a     <font color="blue">negative impact on</font> our stock price</td>
    </tr>
    <tr>
      <td>In  2002, pursuant to our 1995 Stock Option Plan, we approved the     payment of the <font color="blue">exercise price</font> of <font color="blue">options by two</font> of our <font color="blue">directors</font> through the     delivery  of  full-recourse,  interest-bearing promissory notes in the     <font color="blue">aggregate principal amount</font> of <font color="blue">approximately</font> dlra1dtta5 million, secured by a     pledge of the <font color="blue">underlying shares</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, accrued interest     receivable related to the borrowing was dlra284cmam000</td>
    </tr>
    <tr>
      <td>In addition, in 2002 we     executed a <font color="blue">conditional guaranty</font> of a <font color="blue">brokerage margin account</font> for a director     in the amount of dlra500cmam000</td>
    </tr>
    <tr>
      <td>Due to heightened <font color="blue">sensitivity</font> in the current     environment surrounding related-party <font color="blue">transactions</font>, these <font color="blue"><font color="blue">transactions</font> could</font>     be viewed <font color="blue">negatively</font> in the market and our <font color="blue">stock price could</font> be <font color="blue">negatively</font>     affected</td>
    </tr>
    <tr>
      <td>Our <font color="blue">corporate governance policies</font> have <font color="blue">been revised</font> and our 2005     Stock  Incentive  Plan prohibits any <font color="blue">additional</font> loans or <font color="blue">guarantees</font> to     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> has been and <font color="blue">may continue</font> to be volatile</td>
    </tr>
    <tr>
      <td>Historically, the <font color="blue">market price</font> of our <font color="blue">common stock</font> has fluctuated over     a wide range</td>
    </tr>
    <tr>
      <td>In fiscal year 2005, our <font color="blue">common stock</font> traded in a <font color="blue">range from</font>     dlra0dtta70  to  dlra6dtta01</td>
    </tr>
    <tr>
      <td>It is likely that the price of our <font color="blue">common stock</font> will     fluctuate   in   the  future</td>
    </tr>
    <tr>
      <td>The  market  prices  of  securities  of     small-capitalization, <font color="blue">specialty bio<font color="blue">pharmaceutical</font></font> companies, including ours,     from time to time experience <font color="blue">significant</font> price and <font color="blue">volume fluctuations</font>     unrelated to the operating performance of these companies</td>
    </tr>
    <tr>
      <td>In particular,     the <font color="blue">market price</font> of our <font color="blue">common stock</font> may fluctuate <font color="blue"><font color="blue">significant</font>ly</font> due to a     variety of factors, including:       •   our ability to obtain <font color="blue">government</font> contracts to develop vaccines and     other <font color="blue">biological products</font> and <font color="blue">technologies</font>;         •   <font color="blue">government</font>al agency actions including the FDA’s <font color="blue">determination with</font>     respect to new drug <font color="blue">applications</font> for <font color="blue">new products</font>;         •   our ability to obtain financing; and                                         16       _________________________________________________________________             •   our ability to develop <font color="blue">additional</font> products, including <font color="blue">biologicals</font> and     vaccines</td>
    </tr>
    <tr>
      <td>In addition, the occurrence of any of the <font color="blue">risks described</font> in Items 1A     could have a material and <font color="blue">adverse impact on</font> the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>The <font color="blue">conversion</font> of our <font color="blue"><font color="blue">outstanding convertible</font> debt</font>, and the issuance of     shares of our <font color="blue">common stock</font> upon <font color="blue">conversion</font> or exercise of <font color="blue">preferred stock</font>     and/or warrants or in <font color="blue">future offerings would</font> cause dilution of existing     security holders’ interests in the company and may cause the price of our     <font color="blue">common stock</font> to go down</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had <font color="blue">outstanding convertible</font> notes in the     aggregate  principal  amount  of dlra29cmam000cmam000 that as of such date were     <font color="blue">convertible into</font> an aggregate of 5cmam215cmam827 shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The     issuance of shares of our <font color="blue">common stock</font> upon <font color="blue">conversion</font> of such notes, as     well as in connection with future capital raising <font color="blue">activities</font>, would cause     immediate  and  <font color="blue">potentially</font>  substantial  <font color="blue">equity dilution</font> for existing     <font color="blue">stockholders</font>  and  the  price  of our <font color="blue">common stock</font> could be subject to     <font color="blue">significant</font> downward pressure</td>
    </tr>
    <tr>
      <td>We  have <font color="blue">never paid dividends on</font> our <font color="blue">capital stock</font>, and we do not     anticipate paying any <font color="blue">such dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">never paid <font color="blue">cash dividends</font> on</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We currently     anticipate  that  we  will  retain  all of our earnings for use in the     <font color="blue">development</font> of our business and do not anticipate paying any <font color="blue">cash dividends</font>     in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, the terms of our existing and any     <font color="blue">future debt may preclude us from paying dividends</font></td>
    </tr>
    <tr>
      <td>As a result, capital     <font color="blue">appreciation</font>, if any, of our <font color="blue">common stock</font> would be the only source of gain     for <font color="blue">stockholders</font> until dividends are permitted and paid</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our Certificate of Incorporation and By-laws, <font color="blue">Delaware </font>    law, and our <font color="blue">Shareholder Rights Plan </font><font color="blue">could delay</font> or prevent the <font color="blue">acquisition</font>     of  the  company,  even  if  such  <font color="blue">acquisition</font>  would be <font color="blue">beneficial</font> to     <font color="blue">stockholders</font>, and <font color="blue">could impede</font> changes in our Board</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of <font color="blue">Delaware </font><font color="blue">corporate law</font> and our <font color="blue">organizational documents</font>     <font color="blue">could hamper</font> a <font color="blue">third party</font>’s attempt to acquire, or discourage a <font color="blue">third party</font>     from  attempting  to  acquire  control  of, the company</td>
    </tr>
    <tr>
      <td>Moreover, our     <font color="blue">shareholder</font>  rights plan empowers our Board to delay or negotiate, and     thereby possibly thwart, any tender offer or takeover attempt <font color="blue">the Board     </font>opposes</td>
    </tr>
    <tr>
      <td><font color="blue">Stockholders </font>who wish to <font color="blue">participate</font> in these <font color="blue">transactions</font> may not     have the <font color="blue">opportunity</font> to do so</td>
    </tr>
    <tr>
      <td>These provisions also <font color="blue">could limit</font> the price     investors are willing to pay in the future for our securities and make it     more <font color="blue">difficult</font> to change the <font color="blue">composition</font> of our Board in any one year</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions include the right of the Board to issue <font color="blue">preferred stock</font> with     rights senior to those of the <font color="blue">common stock</font> without any <font color="blue">further vote</font> or     action  by <font color="blue">stockholders</font>, the existence of a staggered Board with three     classes of <font color="blue">directors</font> serving staggered three-year terms, advance notice     <font color="blue">requirements</font> for <font color="blue">stockholders</font> to nominate <font color="blue">directors</font> and make proposals, and     a <font color="blue">Delaware </font>statutory provision prohibiting certain <font color="blue">transactions</font> between     Novavax and interested <font color="blue">stockholders</font></td>
    </tr>
  </tbody>
</table>